Other Complications: Food and Drug Administration Investigational Device Exemption Study of the Charité Artificial Disc
| Investigational Group (N = 205) | Control Group (N = 99) | |
|---|---|---|
| All other complications, no. (%) | 9 (4.4) | 4 (4.0) |
| Adjacent level DDD | 2 (1.0) | 1 (1.0) |
| HNP adjacent level | 2 (1.0) | 1 (1.0) |
| Spondylolisthesis | 1 (0.5) | 1 (1.0) |
| Spinal stenosis | 1 (0.5) | 0 |
| Annulus ossification | 1 (0.5) | 0 |
| Calcification resulting in bridging trabecular bone | 1 (0.5) | 0 |
| Other lumbar degenerative | 1 (0.5) | 0 |
| Facet joint degeneration | 0 | 1 |
| Death narcotic related | 1 (0.5) | 0 |
Note. DDD = degenerative disc disease; HNP = herniated nucleus pulposus.